Myeloma research is now benefitting not only myeloma patients but many other cancer patients as well.
Media release following ASCO (American Society of Clinical Oncology) quotes Dr. Brian Durie, chair and co-founder of the International Myeloma Foundation, ” We believe that the clinical and scientific progress in myeloma serves as a roadmap for transforming the treatment of a wide range of cancers.
We are seeing myeloma treatments work in lymphomas, leukemias and even solid tumors. In fact, early data is being presented on utilizing Revlimid in prostate cancer, and evaluating second-generation proteasome inhibitors – carfilzomib and an oral rug from the makers of Velcade – in multiple cancers.”
- Read the media release from the International Myeloma Foundation (IMF)
- Help us fund a cure. Sponsor Team Lorraine.
July 5, 2011 at 1:49 pm
We are not doctors or researchers, but here is what the experts say (more details in the media release mentioned above): Dr Brian G.M. Durie, chair and co-founder of the International Myeloma Foundation, states “We believe that the clinical and scientific progress in myeloma serves as a roadmap for transforming the treatment of a wide range of cancers. We are seeing myeloma treatments work in lymphoma, leukemias and even solid tumours. In fact, early data is being presented on utilizing REVLIMID in prostate cancer, and evaluation second-generation proteasome inhibitors – carfilzomib and an oral drug from the makers of VELCADE – in multiple cancers.”